Follicle-Stimulating Hormone Biological Products: Does Potency Predict Clinical Efficacy?

Follicle-stimulating hormone (FSH), together with luteinizing hormone (LH) and human chorionic gonadotropin (hCG), plays a fundamental role in human reproduction. The discovery of FSH and other gonadotropins was a defining moment in our understanding of reproduction and led to the development of man...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-05, Vol.24 (10), p.9020
Main Authors: Lispi, Monica, Humaidan, Peter, Bousfield, George R, D'Hooghe, Thomas, Ulloa-Aguirre, Alfredo
Format: Article
Language:English
Subjects:
Acids
Biological activity
Biological Products
Chorionic gonadotropin
Chorionic Gonadotropin - pharmacology
Female
Follicle Stimulating Hormone - pharmacology
Follicle Stimulating Hormone, Human - pharmacology
Follicle-stimulating hormone
Follicles
Glycoproteins
Gonadotropin
Gonadotropins
Heterogeneity
Hormones
Human reproduction
Humans
Infertility
Luteinizing hormone
Ovaries
Pharmacodynamics
Pharmacokinetics
Physiology
Pituitary (anterior)
Pituitary gland
Proteins
Reproduction
Review
Signal transduction
Treatment Outcome
Urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Follicle-stimulating hormone (FSH), together with luteinizing hormone (LH) and human chorionic gonadotropin (hCG), plays a fundamental role in human reproduction. The discovery of FSH and other gonadotropins was a defining moment in our understanding of reproduction and led to the development of many treatments for infertility. In this regard, exogenous FSH has been used to treat infertility in women for decades. Today, several recombinant and highly purified urinary forms of FSH are used in medically assisted reproduction (MAR). However, differences in the macro- and micro-heterogeneity of FSH result in a variety of FSH glycoforms, with glycoform composition determining the bioactivity (or potency), pharmacokinetic/pharmacodynamic (PK/PD) profiles, and clinical efficacy of the different forms of FSH. This review illustrates how the structural heterogeneity of FSH glycoforms affects the biological activity of human FSH products, and why potency does not predict effects in humans in terms of PK, PD, and clinical response.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms24109020